Reducing the Risk of Developing Diabetes Chapter 5 Thomas Ransom, Ronald Goldenberg, Amanda Mikalachki, Ally PH Prebtani, Zubin Punthakee Canadian Diabetes.

Slides:

Advertisements

Similar presentations

2003 CDA Clinical Practice Guidelines

Advertisements

Canadian Diabetes Association Clinical Practice Guidelines Hypoglycemia Chapter 14 Dale Clayton, Jean-François Yale, Vincent Woo.

Guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association The Essentials Canadian Diabetes Association.

Canadian Diabetes Assocation Clinical Practice Guidelines Pancreas and Islet Cell Transplant Chapter 20 Breay W. Paty, Angela Koh, Peter Senior.

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*

Produced by The Alfred Workforce Development Team on behalf of DHS Public Health - Diabetes Prevention and Management Initiative June 2005 Diabetes Prevention.

Canadian Diabetes Association Clinical Practice Guidelines Weight Management in Diabetes Chapter 17 Sean Wharton, Arya M. Sharma, David C.W. Lau.

Canadian Diabetes Association Clinical Practice Guidelines Natural Health Products in Type 2 Diabetes Chapter 21 Richard Nahas, Jeannette Goguen.

Canadian Diabetes Association Clinical Practice Guidelines Pharmacologic Management of Type 2 Diabetes Chapter 13 William Harper, Maureen Clement, Ronald.

Screening for Type 1 and Type 2 Diabetes Chapter 4 Jean-Marie Ekoé, Zubin Punthakee, Thomas Ransom, Ally PH Prebtani, Ron Goldenberg Canadian Diabetes.

Canadian Diabetes Association Clinical Practice Guidelines Chronic Kidney Disease in Diabetes Chapter 29 Phil McFarlane, Richard E. Gilbert, Lori MacCallum,

Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.

Canadian Diabetes Association Clinical Practice Guidelines Monitoring for Glycemic Control Chapter 9 Lori Berard, Ian Blumer, Robyn Houlden, David Miller,

Diabetes and Mental Health Chapter 18 David J. Robinson, Meera Luthra, Michael Vallis Canadian Diabetes Association 2013 Clinical Practice Guidelines.

CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.

Canadian Diabetes Assocaition Clinical Practice Guidelines Pharmacotherapy in Type 1 Diabetes Chapter 12 Angela McGibbon, Cindy Richardson, Cheri Hernandez,

Polycystic Ovarian Syndrome

Canadian Diabetes Association Clinical Practice Guidelines Dyslipidemia Chapter 24 G. B. John Mancini, Robert A. Hegele, Lawrence A. Leiter.

Slides current until 2008 Diagnosis, classification and prevention of diabetes Section 1 | 1 of 4 Curriculum Module II–1 | Diagnosis, classification and.

Core Elements.  Recruitment Goals = 48 new participants each year  Recruitment for Intensive Activities 1. Recruitment Team 2. Team Meetings  Invitation.

The Diabetes Prevention Program A U.S. Randomized Clinical Trial to Prevent Type 2 Diabetes in Persons at High Risk.

Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.

Canadian Diabetes Association Clinical Practice Guidelines Neuropathy Chapter 31 Vera Bril, Bruce Perkins, Cory Toth.

Canadian Diabetes Association Clinical Practice Guidelines Screening for the Presence of Coronary Artery Disease Chapter 23 Paul Poirier, Robert Dufour,

Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.

I CAN Prevent Diabetes! Individuals and Communities Acting Now to Prevent Diabetes Recruitment Discussion 2012.

Canadian Diabetes Association Clinical Practice Guidelines Erectile Dysfunction Chapter 33 Gerald Brock, William Harper.

Canadian Diabetes Association Clinical Practice Guidelines Treatment of Diabetes in People with Heart Failure Chapter 28 Jonathan G. Howlett, John C. MacFadyen.

Canadian Diabetes Association Clinical Practice Guidelines Management of Stroke in Diabetes Chapter 27 Michael Sharma, Gord Gubitz.

1 Prediabetes Management. 2 AACE Prediabetes Consensus Statement: Summary Untreated individuals with prediabetes are at increased risk for diabetes as.

Prediabetes Management.

Prevention of Type 2 Diabetes Mellitus

1 Prediabetes Burden. 2 Epidemiology: Health Performance Gaps Prevalence Risk factors –Metabolic syndrome –Obesity Clinical risks of prediabetes –Progression.

Canadian Diabetes Association Clinical Practice Guidelines Physical Activity and Diabetes Chapter 10 Ronald J Sigal, Marni J Armstrong, Pam Colby, Glen.

LONG TERM BENEFITS OF ORAL AGENTS

Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.

Therapy of Type 2 Diabetes Mellitus: UPDATE

Preventing Type 2 Diabetes Selay Lam PGY1, Internal Medicine October 29, 2008.

Prevention of Type 2 Diabetes. Hyperglycemia in Type 2 Diabetes: Changing Treatment Paradigms.

Diabetes: The Modern Epidemic Roy Buchinsky, MD Director of Wellness.

Reducing the Risk of T2DM: What Works?

Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.

Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 1 of 4.

Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.

ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.

Diabetes Prevention for a Heterogeneous Population Richard Arakaki, M.D. Professor of Medicine and Chief, Division of Endocrinology and Metabolism John.

Type 2 Diabetes – A Global Epidemic Arya M Sharma, MD, FRCP(C) Professor of Medicine Research Chair for Obesity Research & Management University of Alberta.

The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.

Prevention of Diabetes Mellitus Prof. Adel El-Etriby Professor of Cardiology Ain Shams Faculty of Medicine.

A Diabetes Outcome Progression Trial

 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.

Prevention Of Diabetes. Type 2 Diabetes: Hyperglycemia Insulin Resistance Relative Impairment of Insulin Secretion Pathogenesis: Poorly Understood Genetic.

The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & Early DM Part 5 Stan Schwartz MD, FACP, FACE.

Diabetes Prevention Program (DPP)

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.

An initiative of South Asian Federation of Endocrine Societies (SAFES)

CDA exercise guidelines 150 minutes moderate – intensity (60 – 70% of max) aerobic over minimum 3 non consecutive days PLUS resistance exercise 3.

Contributions to Type 2 Diabetes. Glucose in balance meal Time in minutes Blood glucose levels, mg/dL Insulin levels, uU/mL Glucagon.

Bariatric Surgery for T2DM The STAMPEDE Trial. A.R. BMI 36.5 T2DM diagnosed age 24 On Metformin, glyburide  insulin Parents with T2DM, father on dialysis.

Guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association CHOICE OF AGENT AFTER INITIAL METFORMIN.

A two stage screening process – the pre-diabetes pathway.

Canadian Diabetes Association Clinical Practice Guidelines Pharmacologic Management of Type 2 Diabetes Chapter 13 (Updated March 2016) William Harper,

Copyright © 2011 American Medical Association. All rights reserved.

Diabetes Mellitus.

Macrovascular Complications Microvascular Complications

Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.

Adequate rest is important for maintaining energy levels and well-being, and all patients should be advised to sleep approximately 7 hours per.

DiRECT (Diabetes Remission Clinical Trial)

Reducing the Risk of Developing Diabetes

New Lipid-Lowering Guidelines

Presentation transcript:

Reducing the Risk of Developing Diabetes Chapter 5 Thomas Ransom, Ronald Goldenberg, Amanda Mikalachki, Ally PH Prebtani, Zubin Punthakee Canadian Diabetes Association 2013 Clinical Practice Guidelines

guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Key Points 1.At this time, there are no safe and effective strategies to prevent T1DM 2.Intensive lifestyle modification with weight loss can reduce the risk of progression from pre-diabetes to T2DM by almost 60% 3.Progression from pre-diabetes to T2DM can be reduced by Metformin or Acarbose by approximately 30% 2013

guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association No Safe and Effective Strategies to Prevent T1DM at this Time T1DM is a chronic autoimmune condition with destruction of pancreatic beta cells Ongoing or completed trials – ENDIT: High-dose nicotinamide – Not effective – DPT-1: Low-dose insulin in high risk relatives – Not effective overall – TRIGR: Exclusion of cow’s milk protein to infants until 6- 8 months of age – Trial ongoing Alternate strategy to use immunosuppression / modulation at the time of diagnosis but significant side effects and ethical considerations

guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Diabetes Prevention Program (DPP) Diabetes Prevention Program (DPP) Research Group. N Engl J Med 2002;346: Years Benefit of diet and exercise or Metformin on diabetes prevention in at-risk patients N = 3234 with IFG and IGT, without diabetes Placebo Metformin Lifestyle Cumulative incidence of diabetes (%)  31%  58% P* < *vs placebo IFG = impaired fasting glucose, IGT = impaired glucose tolerance

guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association STOP-NIDDM Study Effects of Acarbose on the risk of T2DM Chiasson JL, et al. Lancet 2002;359: N = 1429 people with IGT, BMI 25-40, yrs, 3.3 years follow up Days after randomization Cumulative probability P = Acarbose Placebo Acarbose  25%

guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Pharmacology to Reduce Progression to T2DM Metformin has been shown to reduce the incidence of T2DM by approximately 30% in the Diabetes Prevention Program (DPP) Acarbose has been shown to reduce the risk of progression to diabetes by approximately 30% in the Study to Prevent Non-Insulin Dependent Diabetes (STOP-NIDDM) study

guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Recommendation 1 and 2 1.A structured program of lifestyle modification that includes moderate weight loss and regular physical activity should be implemented to reduce risk of T2DM in individuals with IGT [Grade A, Level 1A] or IFG [Grade B, Level 2] or A1C % [Grade D, consensus]. 2.In individuals with IGT, pharmacologic therapy with Metformin [Grade A, Level 1A] or Acarbose [Grade A, level 1A] may be used to reduce the risk of T2DM. 2013

guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association CDA Clinical Practice Guidelines – for professionals BANTING ( ) – for patients